Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes preclinical and clinical evidence on the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, emphasizing mechanisms of blood–brain barrier traversal, tumor-stroma co-option, and brain-specific genomic and transcriptional programs. We summarize advances in therapeutic strategies to combat melanoma brain metastasis including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.
Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes recent advances in understanding the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, with a specific emphasis on brain metastasis. We explore the unique challenges of brain metastasis, including blood-brain barrier penetration, brain-specific microenvironment interactions, and genomic distinctions. Advances in diagnostic tools, such as imaging and liquid biopsies, are discussed alongside current and emerging therapeutic strategies, including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.
Background/Objectives: Despite several FDA-approved therapies, metastatic melanoma remains a major clinical challenge, particularly in patients with brain metastases, which are associated with treatment failure and melanoma-related mortality. The molecular mechanisms underlying the development of melanoma brain metastasis remain incompletely understood. Methods: Building on our prior discovery that AKT1 activates focal adhesion kinase (FAK), we analyzed clinical-genomic data to evaluate the association between PTK2 mRNA expression and overall survival in melanoma cohorts. For functional assessment, we used complementary in vitro and in vivo approaches to investigate the effects of FAK overexpression, FAK activation, FAK kinase-dependence, and expression of FAK-related non-kinase (FRNK) on cell proliferation, migration, and invasion. Complementary syngeneic and genetically engineered mouse models were used to assess tumor growth and metastatic dissemination. Results: High PTK2 (FAK) mRNA expression was associated with shorter overall survival in melanoma cohorts, including patients with BRAF-mutant melanoma treated with BRAF and MEK inhibitors. Pharmacologic MEK inhibition increased FAK phosphorylation at the activating Y397 site, suggesting a potential compensatory response to MAPK pathway inhibition. Functional studies implicated FAK expression and signaling in melanoma cell migration, invasion, tumor growth, and metastatic dissemination. Expression of a kinase dead FAK mutant markedly impaired tumor growth and metastasis in vivo. Conclusions: These findings implicate FAK signaling in melanoma progression and metastatic dissemination. The observed effects of FAK mutants support the further investigation of FAK kinase activity as a therapeutic target. In addition, increased FAK Y397 phosphorylation following MEK inhibition provides a rationale for evaluating combined FAK and MAPK pathway inhibition clinically in patients with advanced melanoma.